Dr. Audrey Garrett, M.D. Psychiatry & Neurology - Geriatric Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 55 Nye Rd, Suite 102, Glastonbury, CT 06033 Phone: 860-657-3056 Fax: 860-633-3517 |
Richard Alan Miller, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 122 A Naubuc Avenue, Glastonbury, CT 06033 Phone: 860-657-3799 |
Dr. Milind Kale, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 140 Glastonbury Blvd Ste 30, Glastonbury, CT 06033 Phone: 860-561-5453 Fax: 860-371-2527 |
Dr. Claudia Mary Carbonari, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 39 Hampshire Dr, Glastonbury, CT 06033 Phone: 860-633-9522 Fax: 860-657-3667 |
Mark Weremchuk, MD Psychiatry & Neurology - Geriatric Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 210 New London Tpke, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 |
Dr. Ian Richard Cameron, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 200 Oak St, Glastonbury, CT 06033 Phone: 860-657-3602 Fax: 860-657-4421 |
Evan Fox, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 300 Hebron Ave, Suite 107, Glastonbury, CT 06033 Phone: 860-430-1150 Fax: 860-430-1093 |
Dr. Harry E. Morgan, M.D. Psychiatry & Neurology - Geriatric Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 55 Nye Rd, Suite 102, Glastonbury, CT 06033 Phone: 860-657-3056 Fax: 860-633-3517 |
Dr. Hasmukh J Shah, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 100 Wood Pond Rd, Glastonbury, CT 06033 Phone: 860-633-0071 |
Primla Fazalud-din, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 31 Sycamore St, Glastonbury, CT 06033 Phone: 860-714-2750 Fax: 860-714-8591 |
Dr. Douglas Eric Chamberlin, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 49 Welles St, Suite 202, Glastonbury, CT 06033 Phone: 860-659-4010 Fax: 860-659-3783 |
Dr. Stephen R Holzman, M.D. Psychiatry & Neurology - Psychiatry Medicare: May Accept Medicare Assignments Practice Location: 200 Oak St, Glastonbury, CT 06033 Phone: 860-657-8868 Fax: 860-657-8802 |
Dr. Naimet A. Syed, M.D. Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 300 Hebron Ave, Suite 215, Glastonbury, CT 06033 Phone: 860-657-4001 |
Mr. Joseph Haddad Iii, Psychiatry & Neurology - Clinical Neurophysiology Medicare: Not Enrolled in Medicare Practice Location: 408 Bell St, Glastonbury, CT 06033 Phone: 860-805-9599 |
Dr. Wayne H Cotton, D.O Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 39 New London Tpke, Suite 230e, Glastonbury, CT 06033 Phone: 860-218-3229 Fax: 860-659-8595 |
News Archive
Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.
Europe remains at risk of a devastating stroke crisis, according to a major new Report, "How Can We Avoid a Stroke Crisis in Europe?" published today, on World Stroke Day, by Action for Stroke Prevention (ASP).
Major depression and coronary artery disease are only modestly related throughout an individual's lifetime, but studying how the two interact over time and in twin pairs paints a more complex picture of the associations between the conditions, according to a report in the August issue of Archives of General Psychiatry. For example, the association between coronary artery disease onset and major depression risk is much stronger over time than vice versa.
Investigators at St. Jude Children's Research Hospital have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to delay treatment to perform costly genetic testing that determines if the patient is at risk for serious treatment side effects, such as neutropenia.
› Verified 2 days ago